JP6320302B2 - 無細胞ｒｎａをプロファイリングおよび定量するための方法 - Google Patents

無細胞ｒｎａをプロファイリングおよび定量するための方法 Download PDF

Info

Publication number
JP6320302B2
JP6320302B2 JP2014554934A JP2014554934A JP6320302B2 JP 6320302 B2 JP6320302 B2 JP 6320302B2 JP 2014554934 A JP2014554934 A JP 2014554934A JP 2014554934 A JP2014554934 A JP 2014554934A JP 6320302 B2 JP6320302 B2 JP 6320302B2
Authority
JP
Japan
Prior art keywords
tissue
rna
cell
specific
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014554934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511122A5 (https=
JP2015511122A (ja
Inventor
リアン チェ ウィンストン コー，
リアン チェ ウィンストン コー，
スティーブン アール． クエイク，
スティーブン アール． クエイク，
ヘイ−ムン クリスティーナ ファン，
ヘイ−ムン クリスティーナ ファン，
ウェンイン パン，
ウェンイン パン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2015511122A publication Critical patent/JP2015511122A/ja
Publication of JP2015511122A5 publication Critical patent/JP2015511122A5/ja
Application granted granted Critical
Publication of JP6320302B2 publication Critical patent/JP6320302B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/21—Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation
    • G06F18/213—Feature extraction, e.g. by transforming the feature space; Summarisation; Mappings, e.g. subspace methods
    • G06F18/2135—Feature extraction, e.g. by transforming the feature space; Summarisation; Mappings, e.g. subspace methods based on approximation criteria, e.g. principal component analysis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • Bioethics (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2014554934A 2012-01-27 2013-01-28 無細胞ｒｎａをプロファイリングおよび定量するための方法 Active JP6320302B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591642P 2012-01-27 2012-01-27
US61/591,642 2012-01-27
PCT/US2013/023471 WO2013113012A2 (en) 2012-01-27 2013-01-28 Methods for profiling and quantitating cell-free rna

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017008768A Division JP2017063799A (ja) 2012-01-27 2017-01-20 無細胞ｒｎａをプロファイリングおよび定量するための方法

Publications (3)

Publication Number Publication Date
JP2015511122A JP2015511122A (ja) 2015-04-16
JP2015511122A5 JP2015511122A5 (https=) 2016-03-03
JP6320302B2 true JP6320302B2 (ja) 2018-05-09

Family

ID=48874081

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014554934A Active JP6320302B2 (ja) 2012-01-27 2013-01-28 無細胞ｒｎａをプロファイリングおよび定量するための方法
JP2017008768A Pending JP2017063799A (ja) 2012-01-27 2017-01-20 無細胞ｒｎａをプロファイリングおよび定量するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017008768A Pending JP2017063799A (ja) 2012-01-27 2017-01-20 無細胞ｒｎａをプロファイリングおよび定量するための方法

Country Status (9)

Country Link
US (15) US20130252835A1 (https=)
EP (2) EP3584327A1 (https=)
JP (2) JP6320302B2 (https=)
CN (2) CN104334742A (https=)
AU (1) AU2013211850B8 (https=)
CA (1) CA2863035C (https=)
HK (1) HK1211624A1 (https=)
SG (2) SG11201505515XA (https=)
WO (1) WO2013113012A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028288A2 (en) 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
JP2013509883A (ja) 2009-11-06 2013-03-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 臓器移植患者における移植片拒絶反応の非侵襲的診断方法
EP2619329B1 (en) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
US20160289762A1 (en) * 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
WO2015069900A1 (en) * 2013-11-06 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
HK1211624A1 (en) 2012-01-27 2016-05-27 The Board Of Trustees Of The University Of The Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
US10689652B2 (en) 2013-10-02 2020-06-23 The Regents Of The University Of California Methods for immortalization of epithelial cells
WO2015069933A1 (en) * 2013-11-06 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Circulating cell-free dna for diagnosis of transplant rejection
AU2014346562B2 (en) 2013-11-07 2018-11-29 The Board Of Trustees Of The Leland Stanford Junior University Cell-free nucleic acids for the analysis of the human microbiome and components thereof
EP4358097A1 (en) 2014-07-25 2024-04-24 University of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
EP3218523B1 (en) 2014-11-14 2020-02-12 Liquid Genomics Inc. Use of circulating cell-free rna for diagnosis and/or monitoring cancer
JP6873921B2 (ja) 2015-05-18 2021-05-19 カリウス・インコーポレイテッド 核酸の集団を濃縮するための組成物および方法
EP3310933B1 (en) * 2015-06-17 2020-11-18 The Translational Genomics Research Institute Methods for obtaining biological molecules from a sample
US10692797B2 (en) * 2015-06-30 2020-06-23 Laird Technologies, Inc. Thermal interface materials with low secant modulus of elasticity and high thermal conductivity
WO2017062517A1 (en) * 2015-10-06 2017-04-13 The Regents Of The University Of California Non-coding rnas linked to immortality and associated methods and compositions
WO2017079384A1 (en) * 2015-11-04 2017-05-11 Metabolon, Inc. Automated sample quality assessment
EP3978627A1 (en) 2016-03-25 2022-04-06 Karius, Inc. Methods using synthetic nucleic acid spike-ins
WO2018191563A1 (en) 2017-04-12 2018-10-18 Karius, Inc. Sample preparation methods, systems and compositions
KR20200003917A (ko) * 2017-05-10 2020-01-10 난토믹스, 엘엘씨 암의 검출, 예측, 및 모니터링을 위한 순환 rna(circulating rna for detection, prediction, and monitoring of cancer)
CN110869518A (zh) * 2017-05-16 2020-03-06 香港中文大学 整合式单细胞和游离血浆rna分析
EP3701043B1 (en) 2017-10-23 2023-11-22 CZ Biohub SF, LLC A noninvasive molecular clock for fetal development predicts gestational age and preterm delivery
CN111526793A (zh) 2017-10-27 2020-08-11 朱诺诊断学公司 用于超低体积液体活检的设备、系统和方法
US11702703B2 (en) 2017-11-07 2023-07-18 Nanthealth Labs, Inc. Targeted cell free nucleic acid analysis
CA3082601A1 (en) 2018-03-16 2019-09-19 Karius, Inc. Sample series to differentiate target nucleic acids from contaminant nucleic acids
US12462935B2 (en) 2018-03-30 2025-11-04 Nucleix Ltd. Deep learning-based methods, devices, and systems for prenatal testing
JP2022504078A (ja) 2018-10-04 2022-01-13 ブルースター ジェノミクス， インコーポレイテッド 単一の生物学的サンプル由来のタンパク質、ヌクレオソームおよび無細胞核酸のシーケンシングベースの同時分析
CN113874525A (zh) * 2018-10-29 2021-12-31 分子听诊器公司 使用无细胞信使rna的骨髓表征
EP4700161A3 (en) 2018-11-21 2026-03-11 Karius, Inc. Direct-to-library methods, systems, and compositions
AU2019403269A1 (en) * 2018-12-18 2021-06-17 Grail, Llc Methods for detecting disease using analysis of RNA
EP3914731A1 (en) * 2019-01-24 2021-12-01 Illumina, Inc. Methods and systems for monitoring organ health and disease
GB2615975B (en) 2019-02-14 2023-11-29 Mirvie Inc Methods and systems for determining a pregnancy-related state of a subject
CA3132030A1 (en) * 2019-04-02 2020-10-08 Dalia Dhingra Methods, systems, and apparatus for nucleic acid detection
AU2020280104A1 (en) 2019-05-22 2022-01-20 Mission Bio, Inc. Method and apparatus for simultaneous targeted sequencing of DNA, RNA and protein
US11948684B2 (en) * 2019-06-20 2024-04-02 Latha Chakravarthy Diagnostic process for disease detection using gene expression based multi layer PCA classifier
CN110964800B (zh) * 2019-09-20 2021-10-22 北京航空航天大学 用于预测早产风险的cfRNA标志物
US11742058B2 (en) 2019-11-05 2023-08-29 Cofactor Genomics, Inc. Methods and systems of processing complex data sets using artificial intelligence and deconvolution
CN115136242A (zh) * 2019-11-08 2022-09-30 雷杰纳荣制药公司 来自大量组织转录组的准确稳健的信息反卷积
EP4077710A4 (en) * 2019-12-20 2024-02-21 University of Utah Research Foundation Methods and compositions for monitoring and diagnosing healthy and disease states
US11475981B2 (en) 2020-02-18 2022-10-18 Tempus Labs, Inc. Methods and systems for dynamic variant thresholding in a liquid biopsy assay
US11211147B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing
US11211144B2 (en) 2020-02-18 2021-12-28 Tempus Labs, Inc. Methods and systems for refining copy number variation in a liquid biopsy assay
CA3172199A1 (en) * 2020-03-18 2021-09-23 Michael Nerenberg Systems and methods of detecting a risk of alzheimer's disease using a circulating-free mrna profiling assay
MX2023001781A (es) * 2020-08-13 2023-04-26 Mirvie Inc Metodos y sistemas para determinar un estado relacionado con el embarazo de un sujeto.
WO2024182491A1 (en) * 2023-02-28 2024-09-06 Virginia Commonwealth University Polygenic risk estimator for cervical length change during pregnancy

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629147A (en) 1992-07-17 1997-05-13 Aprogenex, Inc. Enriching and identifying fetal cells in maternal blood for in situ hybridization
US5432054A (en) 1994-01-31 1995-07-11 Applied Imaging Method for separating rare cells from a population of cells
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
CA2702148C (en) * 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
US20080009467A1 (en) 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US6727066B2 (en) 2000-07-28 2004-04-27 Incyte Corporation Genes expressed in treated human C3A liver cell cultures
US6664056B2 (en) * 2000-10-17 2003-12-16 The Chinese University Of Hong Kong Non-invasive prenatal monitoring
US6977162B2 (en) * 2002-03-01 2005-12-20 Ravgen, Inc. Rapid analysis of variations in a genome
CA2484549A1 (en) 2002-05-10 2003-11-20 Phase-1 Molecular Toxicology, Inc. Liver inflammation predictive genes
AU2003272204A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Neuronal and retinal gene expression patterns
WO2004007673A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Neuronal gene expression patterns
WO2004065629A1 (en) * 2003-01-17 2004-08-05 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
US20060003342A1 (en) * 2004-01-15 2006-01-05 Bianchi Diana W Fetal RNA in amniotic fluid to determine gene expression in the developing fetus
JP2008515384A (ja) * 2004-07-21 2008-05-15 ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 唾液トランスクリプトーム診断
US7713693B1 (en) * 2004-09-01 2010-05-11 University Of Louisiana At Monroe Human cancer cell specific gene transcript
US20060166242A1 (en) * 2005-01-06 2006-07-27 Mount Sinai Hospital Markers of pre-term labor
KR100686816B1 (ko) * 2005-07-22 2007-02-26 삼성에스디아이 주식회사 리튬 이차 전지
EP3591068A1 (en) * 2006-02-02 2020-01-08 The Board of Trustees of the Leland Stanford Junior University Non-invasive fetal genetic screening by digital analysis
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
US20100145131A1 (en) * 2007-05-01 2010-06-10 Helena Grinberg-Rashi Methods and kits for predicting cancer metastasis
WO2009009457A1 (en) 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Alzheimer's disease-specific micro-rna microarray and related methods
HUE019019T5 (en) * 2007-08-22 2017-04-28 Trovagene Inc Methods for Using miRNA for In vivo Cell Death Detection
US8298768B2 (en) * 2007-11-29 2012-10-30 Complete Genomics, Inc. Efficient shotgun sequencing methods
EP2234483A4 (en) * 2008-01-27 2011-04-27 Rosetta Genomics Ltd METHOD AND COMPOSITIONS FOR DIAGNOSIS OF PREGNANCY COMPLICATIONS
WO2009134452A2 (en) * 2008-05-01 2009-11-05 Swedish Health Services Preterm delivery diagnostic assay
WO2009143576A1 (en) 2008-05-27 2009-12-03 Adelaide Research & Innovation Pty Ltd Polymorphisms associated with pregnancy complications
US20110150775A1 (en) * 2008-06-01 2011-06-23 Tufts Medical Center, Inc. Genomic approaches to fetal treatment and diagnosis
US7888030B2 (en) * 2008-08-21 2011-02-15 King's College London Biomarkers
WO2010045470A2 (en) 2008-10-15 2010-04-22 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders
AU2009313851A1 (en) 2008-11-13 2010-05-20 Modgene, Llc Modification of amyloid-beta load in non-brain tissue
WO2011029899A1 (en) 2009-09-11 2011-03-17 The Chinese University Of Hong Kong Methods for assessing liver pathologies
EP2475777A4 (en) * 2009-09-11 2013-03-06 Nugen Technologies Inc COMPOSITIONS AND METHODS FOR COMPLETE TRANSCRIPTOMAL ANALYSIS
CA2807050C (en) * 2009-12-08 2019-06-18 Ozlem Equils Diagnostic biomarker to identify women at risk for preterm delivery
WO2011156763A1 (en) 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Methods for characterizing kidney function
WO2011156734A2 (en) * 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Method of characterizing vascular diseases
US20130116151A1 (en) * 2010-07-08 2013-05-09 Pronota N.V. Biomarker for hypertensive disorders of pregnancy
EP2596132A4 (en) * 2010-07-23 2013-12-18 Harvard College METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
EP3111937B1 (en) 2011-07-08 2020-06-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
CA2838562A1 (en) 2011-08-08 2013-02-14 Eugenia Wang Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
CA3069089A1 (en) 2011-09-22 2013-03-28 Lineage Biosciences, Inc. Compositions and methods for analyzing heterogeneous samples
ES2777002T3 (es) 2011-09-30 2020-08-03 Somalogic Inc Predicción de eventos de riesgo cardiovascular y usos de la misma
EP2773191A2 (en) 2011-10-31 2014-09-10 Merck Sharp & Dohme Corp. Alzheimer's disease signature markers and methods of use
HK1211624A1 (en) 2012-01-27 2016-05-27 The Board Of Trustees Of The University Of The Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
US20160289762A1 (en) * 2012-01-27 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiliing and quantitating cell-free rna
EP2825665B1 (en) 2012-03-14 2017-09-06 Ruprecht-Karls-Universität Heidelberg Epigenetic signatures as marker for cardiomyopathies and myocardial insufficiencies
SG11201506891YA (en) * 2013-03-12 2015-09-29 Agency Science Tech & Res Pre-eclampsia biomarkers
WO2014150198A2 (en) 2013-03-15 2014-09-25 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
EP3303629A1 (en) 2015-06-05 2018-04-11 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
ES2891347T3 (es) 2015-09-14 2022-01-27 Genfit Métodos para diagnosticar y evaluar la esteatohepatitis no alcohólica
US20190071795A1 (en) 2016-03-09 2019-03-07 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions

Also Published As

Publication number Publication date
US20210363584A1 (en) 2021-11-25
US20220213549A1 (en) 2022-07-07
US20160017420A1 (en) 2016-01-21
US20170145508A1 (en) 2017-05-25
HK1211624A1 (en) 2016-05-27
WO2013113012A3 (en) 2014-11-06
EP2807277A4 (en) 2016-02-17
US12365947B2 (en) 2025-07-22
EP3584327A1 (en) 2019-12-25
AU2013211850A8 (en) 2017-06-29
US20220290236A1 (en) 2022-09-15
US10240204B2 (en) 2019-03-26
CA2863035C (en) 2023-08-29
US10287632B2 (en) 2019-05-14
AU2013211850A1 (en) 2014-09-18
JP2017063799A (ja) 2017-04-06
EP2807277A2 (en) 2014-12-03
US20180357379A1 (en) 2018-12-13
WO2013113012A2 (en) 2013-08-01
CA2863035A1 (en) 2013-08-01
AU2013211850B8 (en) 2017-06-29
US20130252835A1 (en) 2013-09-26
US20190226029A1 (en) 2019-07-25
US20170145507A1 (en) 2017-05-25
US20200370121A1 (en) 2020-11-26
US10155986B2 (en) 2018-12-18
US20220042098A1 (en) 2022-02-10
US20220010381A1 (en) 2022-01-13
US20200362416A1 (en) 2020-11-19
US20260055464A1 (en) 2026-02-26
JP2015511122A (ja) 2015-04-16
US10240200B2 (en) 2019-03-26
CN108359711A (zh) 2018-08-03
US20170145509A1 (en) 2017-05-25
SG11201505515XA (en) 2015-09-29
SG10201906331TA (en) 2019-08-27
AU2013211850B2 (en) 2017-03-02
CN104334742A (zh) 2015-02-04

Similar Documents

Publication Publication Date Title
JP6320302B2 (ja) 無細胞ｒｎａをプロファイリングおよび定量するための方法
US20230250477A1 (en) Methods and systems for determining a pregnancy-related state of a subject
US20250306012A1 (en) Circulating rna signatures specific to preeclampsia
AU2013240088A1 (en) Rapid aneuploidy detection
US12359256B2 (en) Circulating RNA signatures specific to preeclampsia
WO2015069900A1 (en) Methods for profiliing and quantitating cell-free rna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180313

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180403

R150 Certificate of patent or registration of utility model

Ref document number: 6320302

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250